Nifty
Sensex
:
:
14330.45
47961.24
-504.40 (-3.40%)
-1630.08 (-3.29%)

Pharmaceuticals & Drugs - API

Rating :
61/99

BSE: 500288 | NSE: MOREPENLAB

38.70
09-Apr-2021
  • Open
  • High
  • Low
  • Previous Close
  •  35.60
  •  39.40
  •  35.30
  •  35.75
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  13279751
  •  5008.86
  •  39.40
  •  13.80

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 1,743.08
  • 21.43
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 1,837.32
  • N/A
  • 4.91

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 34.54%
  • 3.44%
  • 42.34%
  • FII
  • DII
  • Others
  • 0.76%
  • 4.01%
  • 14.91%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.09
  • 11.95
  • 12.04

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 28.07
  • 2.17
  • 1.14

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 21.28
  • 4.31

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 30.58
  • 33.52
  • 26.43

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.89
  • 4.54
  • 3.86

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 13.88
  • 14.94
  • 13.16

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Net Sales
307.42
230.06
33.63%
336.39
213.43
57.61%
257.64
202.98
26.93%
206.60
218.72
-5.54%
Expenses
277.63
214.75
29.28%
304.64
198.37
53.57%
231.07
183.65
25.82%
187.78
196.97
-4.67%
EBITDA
29.79
15.30
94.71%
31.75
15.06
110.82%
26.57
19.33
37.45%
18.83
21.75
-13.43%
EBIDTM
9.69%
6.65%
9.44%
7.05%
10.31%
9.52%
9.11%
9.94%
Other Income
2.84
4.60
-38.26%
3.73
2.81
32.74%
1.33
0.28
375.00%
1.79
1.03
73.79%
Interest
1.27
0.54
135.19%
0.29
0.39
-25.64%
0.29
0.43
-32.56%
0.62
0.93
-33.33%
Depreciation
7.56
8.54
-11.48%
7.68
8.24
-6.80%
8.06
11.50
-29.91%
8.63
11.15
-22.60%
PBT
23.80
10.82
119.96%
27.52
9.24
197.84%
19.55
7.68
154.56%
11.36
10.70
6.17%
Tax
0.01
0.01
0.00%
0.35
5.15
-93.20%
0.19
0.02
850.00%
0.34
0.21
61.90%
PAT
23.79
10.82
119.87%
27.17
4.09
564.30%
19.36
7.66
152.74%
11.02
10.49
5.05%
PATM
7.74%
4.70%
8.08%
1.92%
7.52%
3.77%
5.33%
4.80%
EPS
0.53
0.24
120.83%
0.60
0.09
566.67%
0.43
0.17
152.94%
0.25
0.23
8.70%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
1,108.05
853.07
768.54
606.51
595.47
485.08
400.64
366.85
325.92
289.34
228.30
Net Sales Growth
28.07%
11.00%
26.72%
1.85%
22.76%
21.08%
9.21%
12.56%
12.64%
26.74%
 
Cost Of Goods Sold
731.31
524.19
479.12
361.28
358.35
293.33
238.62
209.04
193.53
178.07
142.68
Gross Profit
376.74
328.87
289.42
245.23
237.12
191.76
162.02
157.81
132.39
111.27
85.62
GP Margin
34.00%
38.55%
37.66%
40.43%
39.82%
39.53%
40.44%
43.02%
40.62%
38.46%
37.50%
Total Expenditure
1,001.12
784.55
701.02
541.78
534.09
423.52
352.41
317.95
294.97
270.11
222.53
Power & Fuel Cost
-
12.56
13.18
11.08
9.84
7.64
7.41
8.42
8.96
9.82
7.69
% Of Sales
-
1.47%
1.71%
1.83%
1.65%
1.57%
1.85%
2.30%
2.75%
3.39%
3.37%
Employee Cost
-
109.91
95.36
76.53
69.69
58.29
48.79
45.08
39.17
36.05
30.52
% Of Sales
-
12.88%
12.41%
12.62%
11.70%
12.02%
12.18%
12.29%
12.02%
12.46%
13.37%
Manufacturing Exp.
-
48.92
31.28
16.21
22.36
13.33
12.68
12.23
11.33
10.20
11.40
% Of Sales
-
5.73%
4.07%
2.67%
3.76%
2.75%
3.16%
3.33%
3.48%
3.53%
4.99%
General & Admin Exp.
-
36.47
36.14
28.52
18.11
18.14
15.89
16.62
13.86
14.37
12.72
% Of Sales
-
4.28%
4.70%
4.70%
3.04%
3.74%
3.97%
4.53%
4.25%
4.97%
5.57%
Selling & Distn. Exp.
-
40.11
32.73
30.04
25.79
23.45
21.40
19.55
20.40
15.85
11.26
% Of Sales
-
4.70%
4.26%
4.95%
4.33%
4.83%
5.34%
5.33%
6.26%
5.48%
4.93%
Miscellaneous Exp.
-
12.39
13.20
18.11
29.95
9.35
7.61
7.01
7.72
5.75
11.26
% Of Sales
-
1.45%
1.72%
2.99%
5.03%
1.93%
1.90%
1.91%
2.37%
1.99%
2.74%
EBITDA
106.94
68.52
67.52
64.73
61.38
61.56
48.23
48.90
30.95
19.23
5.77
EBITDA Margin
9.65%
8.03%
8.79%
10.67%
10.31%
12.69%
12.04%
13.33%
9.50%
6.65%
2.53%
Other Income
9.69
9.48
3.67
3.72
3.72
1.20
1.37
1.22
2.87
1.18
1.04
Interest
2.47
1.98
2.11
4.36
7.56
10.50
8.66
9.92
11.63
7.96
6.27
Depreciation
31.93
36.91
39.90
34.32
33.90
35.20
38.67
45.84
45.80
48.06
48.16
PBT
82.23
39.11
29.18
29.77
23.63
17.06
2.28
-5.64
-23.61
-35.61
-47.62
Tax
0.89
5.53
0.34
0.00
0.00
-0.13
0.14
0.01
-0.01
0.06
-0.69
Tax Rate
1.08%
14.14%
1.17%
0.00%
0.00%
-1.03%
6.14%
-0.36%
0.05%
-0.25%
1.45%
PAT
81.34
33.58
28.85
29.59
23.63
12.80
2.14
-2.77
-20.52
-23.65
-46.93
PAT before Minority Interest
81.34
33.58
28.84
29.77
23.63
12.80
2.14
-2.75
-20.52
-23.63
-46.93
Minority Interest
0.00
0.00
0.01
-0.18
0.00
0.00
0.00
-0.02
0.00
-0.02
0.00
PAT Margin
7.34%
3.94%
3.75%
4.88%
3.97%
2.64%
0.53%
-0.76%
-6.30%
-8.17%
-20.56%
PAT Growth
146.04%
16.40%
-2.50%
25.22%
84.61%
498.13%
-
-
-
-
 
EPS
1.81
0.75
0.64
0.66
0.53
0.28
0.05
-0.06
-0.46
-0.53
-1.04

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
284.06
253.09
225.94
196.26
300.28
287.48
297.11
299.88
320.40
344.05
Share Capital
89.96
89.96
89.96
89.96
209.61
209.61
209.61
209.61
209.61
209.61
Total Reserves
194.10
163.13
135.98
106.30
90.67
77.87
87.50
90.27
110.79
134.44
Non-Current Liabilities
28.42
23.38
20.20
17.80
57.47
74.00
84.65
103.91
122.05
135.01
Secured Loans
0.92
1.83
2.95
1.38
43.41
62.27
74.78
94.65
98.85
114.37
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
15.04
14.32
Long Term Provisions
23.82
19.01
14.42
13.59
11.34
9.22
7.82
7.17
5.73
3.90
Current Liabilities
351.44
339.17
340.12
324.86
166.56
127.92
108.14
102.73
104.95
102.78
Trade Payables
172.30
168.15
174.88
124.88
115.33
84.96
68.60
56.81
64.98
59.79
Other Current Liabilities
165.06
160.64
163.90
198.65
47.04
39.87
37.58
45.22
38.96
41.11
Short Term Borrowings
11.36
8.99
0.00
0.00
0.00
2.23
1.19
0.00
0.00
0.00
Short Term Provisions
2.72
1.39
1.33
1.33
4.19
0.86
0.77
0.70
1.01
1.88
Total Liabilities
663.46
615.18
585.81
538.29
523.68
489.00
489.50
506.09
546.98
581.40
Net Block
216.37
236.21
264.29
271.80
296.72
322.48
368.08
409.46
451.86
496.02
Gross Block
752.55
887.76
997.60
1,026.96
1,018.43
1,009.35
1,004.61
1,000.44
997.38
997.96
Accumulated Depreciation
536.18
651.55
733.31
755.15
721.72
686.87
636.53
590.98
545.52
501.94
Non Current Assets
291.29
315.71
342.37
346.34
366.53
374.42
393.18
415.00
457.37
501.38
Capital Work in Progress
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Non Current Investment
1.08
0.00
0.00
0.00
0.00
0.00
0.00
3.87
3.87
3.97
Long Term Loans & Adv.
73.55
79.22
77.81
73.69
69.82
51.94
25.10
1.67
1.64
1.39
Other Non Current Assets
0.28
0.28
0.27
0.85
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
372.18
299.47
243.44
191.95
157.15
114.58
96.32
91.09
89.61
80.02
Current Investments
0.00
0.02
0.22
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
138.48
94.20
76.89
64.66
42.14
37.11
33.30
37.05
38.66
34.70
Sundry Debtors
137.68
133.75
121.85
92.95
87.94
56.14
42.67
39.11
35.15
29.64
Cash & Bank
38.88
32.21
5.95
7.59
4.36
8.85
9.11
5.53
4.51
2.58
Other Current Assets
57.14
7.86
5.62
4.71
22.71
12.48
11.24
9.40
11.29
13.10
Short Term Loans & Adv.
51.16
31.43
32.92
22.03
16.77
9.34
8.23
6.23
9.60
10.30
Net Current Assets
20.73
-39.70
-96.68
-132.92
-9.41
-13.34
-11.82
-11.64
-15.34
-22.76
Total Assets
663.47
615.18
585.81
538.29
523.68
489.00
489.50
506.09
546.98
581.40

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
11.02
17.37
63.41
40.73
50.07
50.70
33.52
33.64
27.11
11.13
PBT
39.11
29.18
29.77
23.04
17.06
2.28
-5.64
-23.60
-35.61
-47.62
Adjustment
36.63
40.32
38.64
41.40
45.69
47.32
55.76
56.80
55.99
54.44
Changes in Working Capital
-58.84
-51.78
-5.00
-23.72
-8.41
1.23
-19.50
-2.64
-5.25
3.63
Cash after chg. in Working capital
16.89
17.71
63.41
40.73
54.34
50.83
30.62
30.56
15.13
10.45
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-5.88
-0.34
0.00
0.00
0.13
-0.13
0.01
0.01
-0.06
0.68
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
-4.40
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-12.46
-13.05
-26.93
-13.60
-27.30
-31.65
-0.80
-2.83
-3.35
-4.05
Net Fixed Assets
135.60
113.16
31.96
-8.08
-7.02
-4.73
-4.09
-2.87
0.60
-2.41
Net Investments
-1.07
0.20
-0.22
0.00
0.25
0.00
3.87
0.00
0.10
0.00
Others
-146.99
-126.41
-58.67
-5.52
-20.53
-26.92
-0.58
0.04
-4.05
-1.64
Cash from Financing Activity
5.49
-0.44
-37.77
-23.72
-27.26
-19.31
-29.14
-29.79
-21.83
-5.60
Net Cash Inflow / Outflow
4.04
3.88
-1.29
3.40
-4.49
-0.26
3.58
1.02
1.93
1.48
Opening Cash & Equivalents
9.60
5.72
7.00
3.60
8.85
9.11
5.53
4.51
2.58
1.10
Closing Cash & Equivalent
13.64
9.60
5.72
7.00
4.36
8.85
9.11
5.53
4.51
2.58

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
6.32
5.63
5.02
4.36
4.02
3.73
3.95
4.01
4.46
4.99
ROA
5.25%
4.80%
5.30%
4.45%
2.53%
0.44%
-0.55%
-3.90%
-4.19%
-7.84%
ROE
12.50%
12.04%
14.10%
12.54%
7.35%
1.24%
-1.54%
-10.77%
-11.12%
-18.99%
ROCE
10.25%
10.01%
14.05%
10.18%
6.29%
2.90%
1.80%
-2.09%
-3.40%
-8.22%
Fixed Asset Turnover
1.04
0.82
0.60
0.58
0.49
0.41
0.37
0.33
0.29
0.23
Receivable days
58.07
60.70
64.63
55.44
53.22
44.17
40.16
40.83
40.35
42.17
Inventory Days
49.78
40.63
42.59
32.73
29.27
31.48
34.55
41.63
45.68
52.36
Payable days
79.06
88.85
103.38
82.97
83.88
76.01
67.69
69.30
75.59
101.91
Cash Conversion Cycle
28.78
12.48
3.85
5.20
-1.39
-0.36
7.02
13.16
10.44
-7.39
Total Debt/Equity
0.47
0.52
0.06
0.25
0.22
0.28
0.30
0.37
0.38
0.39
Interest Cover
20.71
14.83
7.83
4.13
2.21
1.26
0.72
-0.77
-1.96
-6.59

News Update:


  • Morepen Laboratories eyeing multi-billion dollar global API market
    12th Feb 2021, 15:03 PM

    Global patent expiry for these new molecules is slated in next 5-6 years

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.